IL1A and COVID-19: Although the anti-IL-6 receptor monoclonal antibody, tocilizumab, has been used to treat COVID-19 patients (13, 14), any and all therapies that reduce the activities of either IL-1β or IL-1α consistently reduce circulating levels of IL-6 (5, 11).